A mucoadhesive composition including denture adhesive composition comprising: (i) 10 to about 75 wt. % of a maleic acid or anhydride copolymer; (ii) 10 to about 50 wt. % of a cellulose ether; (iii) 0.1 to 10 wt. % of a crosslinked polyvinyl pyrrolidone that is swellable but not soluble in water; and (iv) 30 to 70 wt. % of an orally acceptable carrier based on the total weight of the composition. Also disclosed is a method of use thereof and a process lot preparing the same.

This disclosure provides novel aqueous povidone-iodine (PVP-I) pharmaceutical preparations, which demonstrate strong antimicrobial activity and also strong virucidal activities. The disclosure also provides methods for reducing virus transmission or decreasing risk, incidence or severity of diseases (e.g., COVID-19) or conditions caused by virus infections by topically applying the pharmaceutical preparation of the disclosure to an animal (e.g., a human subject). The disclosure further provides methods of reducing an infection risk posed by microorganisms or viruses in a clinical setting.

This disclosure provides novel aqueous povidone-iodine (PVP-I) pharmaceutical preparations, which demonstrate strong antimicrobial activity and also strong virucidal activities. The disclosure also provides methods for reducing virus transmission or decreasing risk, incidence or severity of diseases (e.g., COVID-19) or conditions caused by virus infections by topically applying the pharmaceutical preparation of the disclosure to an animal (e.g., a human subject). The disclosure further provides methods of reducing an infection risk posed by microorganisms or viruses in a clinical setting.

A pharmaceutical composition for treating skin infections is described herein. A method using a pharmaceutical composition for treating skin infections is described herein. A pharmaceutical composition for treating skin infections may comprise, in 100 parts of the composition, 1-99 parts of a pharmaceutically acceptable excipient; 99-1 parts of a keratolytic; 99-1 parts ethyl pyruvate; and 99-1 parts povidone iodine. A method for treating skin infections may comprise topical application of a composition to an infected skin cell for a treatment period.

A pharmaceutical composition for treating skin infections is described herein. A method using a pharmaceutical composition for treating skin infections is described herein. A pharmaceutical composition for treating skin infections may comprise, in 100 parts of the composition, 1-99 parts of a pharmaceutically acceptable excipient; 99-1 parts of a keratolytic; 99-1 parts ethyl pyruvate; and 99-1 parts povidone iodine. A method for treating skin infections may comprise topical application of a composition to an infected skin cell for a treatment period.

Provided herein are antioxidant, thermally-responsive copolymer-based compositions and methods of making and using the compositions, e.g., for treatment of ischemia reperfusion injury in a patient. The copolymer comprises a hydrocarbyl backbone, and a plurality of pendant pyrrolidone, antioxidant radical, polyester oligomer, and N-alkyl amide groups.

Provided herein are antioxidant, thermally-responsive copolymer-based compositions and methods of making and using the compositions, e.g., for treatment of ischemia reperfusion injury in a patient. The copolymer comprises a hydrocarbyl backbone, and a plurality of pendant pyrrolidone, antioxidant radical, polyester oligomer, and N-alkyl amide groups.

The present disclosure provides a liquid formulation comprising: (a) RK-33, (b) cholic acid or derivative thereof, (c) a water-soluble polyvinyl polymer, and (d) water. The disclosure also provides a method of making a liquid formulation comprising RK-33. The disclosure further provides a method of treating cancer in a subject in need thereof, the method comprising (a) diluting the formulation of the present disclosure to form a diluted formulation, and (b) intravenously administering to the subject the diluted formulation.

The present disclosure provides a liquid formulation comprising: (a) RK-33, (b) cholic acid or derivative thereof, (c) a water-soluble polyvinyl polymer, and (d) water. The disclosure also provides a method of making a liquid formulation comprising RK-33. The disclosure further provides a method of treating cancer in a subject in need thereof, the method comprising (a) diluting the formulation of the present disclosure to form a diluted formulation, and (b) intravenously administering to the subject the diluted formulation.

A method of reducing a friction coefficient of a surface is disclosed herein, comprising attaching a water-soluble polymer to the surface, and contacting the water-soluble polymer with liposomes, thereby coating the surface with an amphiphilic lipid. Further disclosed herein are solutions comprising a water-soluble polymer attachable to the surface, liposomes, and an aqueous carrier, for reducing a friction coefficient of a surface, and methods utilizing same. Articles of manufacture comprising a substrate coated by a water-soluble polymer which is coated by an amphiphilic lipid are also described, as are uses and methods for treating a synovial joint disorder associated with increased articular friction.